Feasibility and acceptability of injectable artesunate for the treatment of severe malaria in the Democratic Republic of Congo

详细信息    查看全文

• 作者：Henry M. T. Ntuku ; Gianfrancesco Ferrari ; Christian Burri…
• 关键词：Malaria ; Severe malaria ; Injectable artesunate ; Injectable quinine ; Feasibility ; Democratic Republic of the Congo
• 刊名：Malaria Journal
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：15
• 期：1
• 全文大小：2,601 KB
• 参考文献：1.PNLP. Plan Stratégique National de Lutte contre le Paludisme 2013–2015. Kinshasa: Ministère de la Santé; 2013.
  2.WHO. World malaria report. Geneva: World Health Organization; 2013.
  3.PNLP. Rapport annuel d’activités 2012. Kinshasa: Ministère de la Santé; 2013.
  4.Likwela JL, Donnen P, Dramaix MW. Clinical aspects and outcome of suspected severe pediatric malaria. Méd Mal Infect. 2012;42:315–20.CrossRef
  5.Roll Back MalariaPartnership. Refined/Updated GMAP Objectives, Targets, Milestones and Priorities Beyond 2011. Geneva: Roll Back Malaria; 2011.
  6.Sinclair D, Donegan S, Isba R, Lalloo D. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012;6:CD005967.PubMed
  7.Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366:717–25.PubMed CrossRef
  8.Dondorp AM, Fanello CI, Hendriksen ICE, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647–57.PubMed PubMedCentral CrossRef
  9.WHO. Management of severe malaria. A practical handbook. Geneva: World Health Organization; 2013.
  10.WHO. Guidelines for treatment of malaria. 2nd ed. Geneva: World Health Organization; 2011.
  11.Saving more lives with injectable artesunate. Injectable Artesunate Stakeholders’ Meeting Report. 2012. http://​www.​mmv.​org/​sites/​default/​files/​uploads/​docs/​publications/​Injectable Artesunate Stakeholders Meeting Report.pdf. Accessed 15 Dec 2014.
  12.PNLP. Directives nationales de traitement du paludisme en République Démocratique du Congo. Kinshasa: Ministère de la Santé; 2012.
  13.Burri C, Ferrari G, Ntuku HM, Tshefu AK, Duparc S, Hugo P, et al. Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo: a manageable issue. Am J Trop Med Hyg. 2014;91:821–3.PubMed PubMedCentral CrossRef
  14.Rolling T, Agbenyega T, Issifou S, Adegnika A, Sylverken J, Spahlinger D, et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria—a double-center prospective study. J Infect Dis. 2014;209:1921–8.PubMed CrossRef
  15.Rolling T, Wichmann D, Schmiedel S, Burchard GD, Kluge S, Cramer JP. Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis. Malar J. 2013;12:241.PubMed PubMedCentral CrossRef
  16.Ferrari G, Ntuku HM, Burri C, Tshefu AK, Duparc S, Hugo P, et al. An operational comparative study between quinine and artesunate for the treatment of severe malaria in Hospitals and Health Centres of Kinshasa and Bas Congo in the Democratic Republic of Congo: the MATIAS study. Malar J. 2015;14:226.PubMed PubMedCentral CrossRef
  17.Malaria Atlas Project. Democratic Republic of Congo, Malaria risk; 2010. http://​www.​map.​ox.​ac.​uk/​explore/​countries/​COD/​ .
  18.Taylor SM, Messina JP, Hand CC, Juliano J, Muwonga J, Tshefu AK, et al. Molecular malaria epidemiology: mapping and burden estimates for the Democratic Republic of the Congo, 2007. PLoS One. 2011;6:e16420.PubMed PubMedCentral CrossRef
  19.Alkadi HO. Antimalarial drug toxicity: a review. Chemotherapy. 2007;53:385–91.PubMed CrossRef
  20.Taylor W, White N. Antimalarial drug toxicity: a review. Drug Saf. 2004;27:25–61.PubMed CrossRef
  21.Wolf LR, Otten EJ, Spadafora M. Cinchonism: two case reports and review of acute quinine toxicity and treatment. J Emerg Med. 1992;10:295–301.PubMed CrossRef
  22.Sam-wobo SO, Agbeyangi OA, Ekpo UF, Akinloye OA, Mafiana CF, Adeleke MA. Rectal artesunates, their utilization, and parental perception in the management of malaria in children from Abeokuta, Southwestern Nigeria. Vector-Borne Zoonotic Dis. 2012;12:151–5.PubMed CrossRef
  23.MSF. Making the Switch. Ensuring access to improved treatment for severe malaria in Africa. Geneva; 2011. http://​www.​msf.​org/​article/​malaria-making-switch .
  
• 作者单位：Henry M. T. Ntuku (1) (2) (3)
  Gianfrancesco Ferrari (2) (3)
  Christian Burri (2) (3)
  Antoinette K. Tshefu (1)
  Didier M. Kalemwa (2) (3)
  Christian Lengeler (2) (3)
  
  1. Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo
  2. Swiss Tropical and Public Health Institute, Basel, Switzerland
  3. University of Basel, Basel, Switzerland
  
• 刊物主题：Parasitology; Infectious Diseases; Tropical Medicine;
• 出版者：BioMed Central
• ISSN：1475-2875

文摘

Background The Democratic Republic of the Congo (DRC) changed its national policy for the treatment of severe malaria in both children and adults in 2012 from intravenous quinine to injectable artesunate. The country is now planning to deploy nationwide injectable artesunate as the preferred treatment for the management of severe malaria. To support this process, the feasibility and acceptability of the use of injectable artesunate in the context of the DRC was assessed, from the perspective of both health care providers and patients/caretakers.